1. Metformin and Diabetes Prevention in Patients with Prediabetes: Results from Isfahan Diabetes Prevention Study (IDPS)
- Author
-
Ashraf Aminorroaya, Parisa Khodabandeh Shahraki, Awat Feizi, Mahboubeh Farmani, and Massoud Amini
- Subjects
medicine.medical_specialty ,Diabetes risk ,endocrine system diseases ,business.industry ,Hazard ratio ,nutritional and metabolic diseases ,Type 2 diabetes ,medicine.disease ,Impaired fasting glucose ,Metformin ,Impaired glucose tolerance ,Internal medicine ,Diabetes mellitus ,medicine ,Prediabetes ,business ,medicine.drug - Abstract
Aim: Although, the effectiveness of metformin in diabetes treatment is well established, its preventive effect in the development of diabetes is still unclear in real world. We aimed to determine the effectiveness of metformin therapy as a single preventive agent in patients with prediabetes in a cohort study (IDPS). Study Design: In this prospective observational study. Place and Duration of Study: Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Methodology: We included 410 patients with prediabetes (168 metformin user, 242 non-users), who participated in IDPS. To determine the association between metformin use and incidence of type 2 diabetes, Cox proportional hazard method, Kaplan-Meier and log Rank test were used. Results: In fully adjusted model for all confounders, significant hazard ratio (HR) for staying prediabetes rather than returning to normal was detected in male group of metformin non-user (HR: 2·41 [95% CI 1.01-5.79]; P
- Published
- 2021
- Full Text
- View/download PDF